Service d'Oncologie Multidisciplinaire et Innovations Thérapeutiques, Université de la Méditerranée-Assistance Publique Hôpitaux de Marseille, Marseille, France.
Anticancer Drugs. 2011 Mar;22(3):199-205. doi: 10.1097/CAD.0b013e328341ccdd.
Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor prognosis, whose exposure to asbestos fibers is the main etiology. The incidence of MPM is anticipated to increase worldwide during the first half of this century. MPM is notoriously refractory to most treatments, and the only standard of care is cisplatin and antifolate first-line chemotherapy. The urgent need for additional therapeutic agents, in parallel with advances in the knowledge of the molecular events of oncogenesis, has resulted in the development of the so-called 'targeted agents' that specifically inhibit critical pathways in malignant cells and in their microenvironment. We carried out a comprehensive review of the literature from January 2000 to May 2010 on studies that assessed targeted agents for the systemic treatment of MPM. Although tyrosine kinase inhibitors directed against the epidermal growth factor and the platelet-derived growth factor receptors did not show significant clinical activity in phase II studies, some other targeted therapies seemed promising, notably histone deacetylase inhibitors and antiangiogenic agents. However, none of these has yet reached daily practice. That is the reason why efforts must continue in the area of clinical and translational research for MPM.
恶性胸膜间皮瘤（MPM）是一种预后不良的侵袭性肿瘤，其暴露于石棉纤维是主要病因。预计在本世纪上半叶，全球 MPM 的发病率将增加。MPM 对大多数治疗方法都具有明显的耐药性，唯一的标准治疗方法是顺铂和叶酸拮抗剂一线化疗。在对致癌分子事件的认识不断深入的同时，迫切需要额外的治疗药物，这导致了所谓的“靶向药物”的发展，这些药物专门抑制恶性细胞及其微环境中的关键途径。我们对 2000 年 1 月至 2010 年 5 月间评估靶向药物治疗 MPM 的系统性治疗的研究进行了全面的文献回顾。尽管针对表皮生长因子和血小板衍生生长因子受体的酪氨酸激酶抑制剂在 II 期研究中并未显示出显著的临床活性，但其他一些靶向治疗方法似乎很有前途，特别是组蛋白去乙酰化酶抑制剂和抗血管生成剂。然而，这些方法都尚未达到日常实践的水平。这就是为什么必须在 MPM 的临床和转化研究领域继续努力的原因。
